Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (201 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544398604498 |
---|---|
ctrlnum |
(CKB)4920000000094249 (oapen)https://directory.doabooks.org/handle/20.500.12854/51977 (EXLCZ)994920000000094249 |
collection |
bib_alma |
record_format |
marc |
spelling |
Mary M. Torregrossa auth Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models Long-Term Consequences of Adolescent Drug Use Frontiers Media SA 2018 1 electronic resource (201 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment. Behaviorally, adolescents are more likely to engage in risky activities and make impulsive decisions. As such, the majority of substance use begins in adolescence, and an earlier age of onset of use (<15 yr) is strongly associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug use may negatively impact ongoing neurological development, which could lead to long-term cognitive and emotional deficits. A large number of clinical studies have investigated both the acute and long-term effects of adolescent drug use on functional outcomes. However, the clinical literature contains many conflicting findings, and is often hampered by the inability to know if functional differences existed prior to drug use. Moreover, in human populations it is often very difficult to control for the numerous types of drugs, doses, and combinations used, not to mention the many other environmental factors that may influence adult behavior. Therefore, an increase in the number of carefully controlled studies using relevant animal models has the potential to clarify which adolescent experiences, particularly what drugs used when, have long-term negative consequences. Despite the advantages of animal model systems in clarifying these issues, the majority of pre-clinical addiction research over the past 50+ years has been conducted in adult animals. Moreover, few addiction-related studies have investigated the long-term neurocognitive consequences of drug exposure at any age. In the past 10 years of so, however, the field of adolescent drug abuse research has burgeoned. To date, the majority of this research has focused on adolescent alcohol exposure using a variety of animal models. The results have given the field important insight into why adolescents are more likely to drink alcohol to excess relative to adults, and the danger of adolescent alcohol use (e.g., in leading to a persistence of excessive drinking in adulthood). More recently, research regarding the effects of adolescent exposure to other drugs of abuse, including nicotine, cocaine, and cannabinoids has expanded. Therefore, we are at unique point in time, when emerging results from carefully controlled pre-clinical studies can inform the sometimes confusing clinical literature. In addition, we expect an influx of prospective clinical studies in response to a cross-institute initiative at NIH, known as the ABCD grant. Several institutes are enrolling children prior to adolescence (and the initiation of drug use), in order to control for pre-existing neurobiological and neurobehavioral differences and to monitor the age of initiation and amount of drug used more carefully than is possible using retrospective designs. English alcohol stress nicotine cocaine ketamine methamphetamine cannabinoid prefrontal cortex juvenile sex differences 2-88945-530-0 Jacqueline M. Barker auth Shannon L. Gourley auth |
language |
English |
format |
eBook |
author |
Mary M. Torregrossa |
spellingShingle |
Mary M. Torregrossa Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models Frontiers Research Topics |
author_facet |
Mary M. Torregrossa Jacqueline M. Barker Shannon L. Gourley |
author_variant |
m m t mmt |
author2 |
Jacqueline M. Barker Shannon L. Gourley |
author2_variant |
j m b jmb s l g slg |
author_sort |
Mary M. Torregrossa |
title |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_full |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_fullStr |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_full_unstemmed |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_auth |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_alt |
Long-Term Consequences of Adolescent Drug Use |
title_new |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
title_sort |
long-term consequences of adolescent drug use: evidence from pre-clinical and clinical models |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (201 p.) |
isbn |
2-88945-530-0 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT marymtorregrossa longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels AT jacquelinembarker longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels AT shannonlgourley longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels AT marymtorregrossa longtermconsequencesofadolescentdruguse AT jacquelinembarker longtermconsequencesofadolescentdruguse AT shannonlgourley longtermconsequencesofadolescentdruguse |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094249 (oapen)https://directory.doabooks.org/handle/20.500.12854/51977 (EXLCZ)994920000000094249 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1787548761604489216 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04301nam-a2200421z--4500</leader><controlfield tag="001">993544398604498</controlfield><controlfield tag="005">20231214133604.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094249</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/51977</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094249</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mary M. Torregrossa</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Long-Term Consequences of Adolescent Drug Use</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (201 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment. Behaviorally, adolescents are more likely to engage in risky activities and make impulsive decisions. As such, the majority of substance use begins in adolescence, and an earlier age of onset of use (<15 yr) is strongly associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug use may negatively impact ongoing neurological development, which could lead to long-term cognitive and emotional deficits. A large number of clinical studies have investigated both the acute and long-term effects of adolescent drug use on functional outcomes. However, the clinical literature contains many conflicting findings, and is often hampered by the inability to know if functional differences existed prior to drug use. Moreover, in human populations it is often very difficult to control for the numerous types of drugs, doses, and combinations used, not to mention the many other environmental factors that may influence adult behavior. Therefore, an increase in the number of carefully controlled studies using relevant animal models has the potential to clarify which adolescent experiences, particularly what drugs used when, have long-term negative consequences. Despite the advantages of animal model systems in clarifying these issues, the majority of pre-clinical addiction research over the past 50+ years has been conducted in adult animals. Moreover, few addiction-related studies have investigated the long-term neurocognitive consequences of drug exposure at any age. In the past 10 years of so, however, the field of adolescent drug abuse research has burgeoned. To date, the majority of this research has focused on adolescent alcohol exposure using a variety of animal models. The results have given the field important insight into why adolescents are more likely to drink alcohol to excess relative to adults, and the danger of adolescent alcohol use (e.g., in leading to a persistence of excessive drinking in adulthood). More recently, research regarding the effects of adolescent exposure to other drugs of abuse, including nicotine, cocaine, and cannabinoids has expanded. Therefore, we are at unique point in time, when emerging results from carefully controlled pre-clinical studies can inform the sometimes confusing clinical literature. In addition, we expect an influx of prospective clinical studies in response to a cross-institute initiative at NIH, known as the ABCD grant. Several institutes are enrolling children prior to adolescence (and the initiation of drug use), in order to control for pre-existing neurobiological and neurobehavioral differences and to monitor the age of initiation and amount of drug used more carefully than is possible using retrospective designs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alcohol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nicotine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cocaine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ketamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methamphetamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabinoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prefrontal cortex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">juvenile</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sex differences</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-530-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jacqueline M. Barker</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shannon L. Gourley</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:58:37 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337582150004498&Force_direct=true</subfield><subfield code="Z">5337582150004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337582150004498</subfield></datafield></record></collection> |